Novelogics Biotechnology Inc
Novelogics is developing antibody immunotherapies for cancer. They have identified an overlooked area in cancer biology that may represent a missing piece of the ‘cancer treatment puzzle’. Unlike antibody drugs that attach directly to cells, our proprietary "antibody immunotherapy" acts as an “Interceptor” of unattached immunosuppressive proteins that have the capacity to shut down critical cancer-killing immune cells. This therapeutic is specifically designed to enable effective restoration of these immune cells and to limit further immune suppression, thereby facilitating safe treatment for cancer patients while significantly extending their overall survival times and improving their quality of life. Novelogics believes that the unique mechanism of action of their therapeutic antibody will allow it to be effectively and rationally combined with other leading cancer drugs. One exceptional combination has already been identified and demonstrated proof of concept in mouse models in prostate cancer.
Conference Objective
Seeking staged investments and/or partnering
Delegate Contacts
Dr. Cheney has over 20 years of experience in the biopharmaceutical industry both in Canada and the U.S. He has extensive knowledge of small molecule and biologics drug discovery as well as pre-clinical development. As President, Dr. Cheney has set the vision and guided the Company from early start-up phase to the pre-clinical development phase.
Ms. Allison has over 25 years of experience in corporate leadership roles and management consulting including five years of experience in the Biotech sector. She has worked for a number of corporations and has held key positions in both Business Development and Marketing, and raising Capital to drive the company forward